The Impact of COVID-19 on the Epidemiology and Outcomes of Candidemia: A Retrospective Study from a Tertiary Care Center in Lebanon
Preprint
- 11 May 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Invasive fungal infections, notably candidemia, have been associated with COVID-19. The epidemiology of candidemia has significantly changed during the COVID-19 pandemic. We aim to identify the microbiological profile, resistance rates, and outcomes of COVID-19 associated candidemia (CAC) compared to patients with candidemia not associated with COVID-19. We retrospectively collected data on patients with candidemia admitted to the American University of Beirut Medical Center between 2004 and 2022. We compared the epidemiology of candidemia during and prior to the COVID-19 pandemic. Additionally, we compared the outcomes of critically ill patients with CAC to those with candidemia without COVID-19 from March 2020 till March 2022. Among 245 candidemia episodes, 156 occurred prior to the pandemic and 89 during the pandemic. Of the latter, 39 (43.8%) were CAC, most of which (82%) were reported from intensive care units (ICU). Non-albicans Candida (NAC) spp. were predominant throughout the study period (67.7%). Candida auris infection was the most common cause of NAC spp. in CAC. C. glabrata had decreased susceptibility rates to fluconazole and caspofungin during the pandemic period (46.1% and 38.4% respectively). Mortality rate in the overall ICU population during the pandemic was 76.6%, much higher than the previously reported mortality of candidemia from previous studies at our center. There was no significant difference in 30-day mortality between CAC and non-CAC (75.0% vs 78.1%; P =0.76). Performing ophthalmic examination (P = 0.002), CVC removal during the 48 hours following the candidemia (P = 0.008) and identifying the Candida spp. (P = 0.028) were significantly associated with a lower case-fatality rate. The epidemiology of candidemia has been significantly affected by the COVID-19 pandemic at our center. Rigorous infection control measures and proper antifungal stewardship are essential to combat highly resistant species like C. auris.Keywords
All Related Versions
- Version 1, 2023-05-11, Preprints
- Published version: Journal of Fungi, 9 (7), 769.
This publication has 45 references indexed in Scilit:
- Prevalence of Fungal Drug Resistance in COVID-19 Infection: a Global Meta-analysisCurrent Fungal Infection Reports, 2022
- COVID-19 Pathogenesis and Clinical ManifestationsInfectious Disease Clinics of North America, 2022
- Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-AnalysisInternational Journal of Infectious Diseases, 2021
- Epidemiology and burden of invasive fungal infections in the countries of the Arab LeagueJournal of Infection and Public Health, 2020
- Usefulness of EQUAL Candida Score for predicting outcomes in patients with candidaemia: a retrospective cohort studyClinical Microbiology and Infection, 2020
- Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysisClinical Microbiology and Infection, 2019
- Utility of Ophthalmologic Screening for Patients With Candida Bloodstream InfectionsJAMA Ophthalmology, 2019
- Time of catheter removal in candidemia and mortalityThe Brazilian Journal of Infectious Diseases, 2018
- Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogenMicrobiologyopen, 2018
- Candidaemia in the non-neutropenic patient: A critique of the guidelinesInternational Journal of Antimicrobial Agents, 2013